Imidazofurin

The dried roots of Angelica dahurica (Fisch. ex Hoffm.) Benth.et Hook.f. var. formosana (Boiss.) Shan et Yuan, a traditional medicinal herb known as hangbaizhi , is significant in food and pharmaceutical applications. However, genetic diversity challenges standardized production. This study characterized the secondary metabolite profiles, particularly coumarins, in a newly bred variety of hangbaizhi (NAD) and compared them with traditional cultivars (TAD). Using ultra‐high‐performance liquid chromatography‐tandem mass spectrometry integrated with computational strategies, including polygonal mass defect filtering, expanded virtual formula library screening, feature‐based molecular networking, and network annotation propagation, we annotated 95 coumarins (43 simple coumarins, 45 furanocoumarins, and seven dihydrofuranocoumarins) across confidence levels. Multivariate analyses (principal component analysis, orthogonal partial least squares discriminant analysis, and volcano plot) revealed significant metabolic divergence between NAD and TAD. NAD exhibited enriched furanocoumarins and reduced dihydrofuranocoumarins compared to TAD. The newly bred variety demonstrated superior phenotypic homogeneity and distinct coumarin signatures, providing a scientific foundation for quality control and functional food applications. This study also establishes a methodological framework for secondary metabolite profiling in plant breeding programs.

Patients with severe asthma (SA) experience significant morbidity, due to high exacerbation rates and frequent use of oral corticosteroids (OCS). In randomized trials, biologic therapies (biologics) consistently improve SA outcomes. Using pharmacy claims data, the AUBOCIAS study estimated OCS use before and after initiation of biologics, and yearly trend of biologics use among SA patients.

Anonymized dispensation data from pharmacies (IQVIA Switzerland LRx network) were retrieved between 2018 and 2023. SA patients aged ≥12 were identified by regular use of fixed-dose combinations over ≥12 months, or OCS, or any biologics used for SA. Main outcome was the change in total annual dose (TAD) of OCS after initiation of biologics.

In 2023, among a total of 26,146 patients with likely asthma, 3882 (10.6 %) were identified as having SA. The mean age was 61 years and 57.0 % were females. Of those 63.0 % were using OCS, with a mean TAD of 1760 mg. Initiations of biologics for SA increased from 0.4 % (2018) to 14.3 % (2023). Over the study period, among 532 biologics initiators, 282 (53.0 %) used OCS: 87 patients (36.0 %) could be weaned (p < 0.0001). Among persistent OCS users, the mean TAD decreased from 1200-375 mg (-68.8 %; p < 0.0001).

In Switzerland, 10.6 % of patients with likely asthma identified in the LRx database were considered to have SA. OCS were frequently used at high TAD, while biologics were increasingly initiated. Most biologics initiators were able to reduce or discontinue OCS.